Clinical Trial Info

SCB-2019 as COVID-19 Vaccine

Authored by

This is a randomized, double blind, placebo controlled, first-in-human (FIH) Phase 1 study to assess safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels, administered as 2 injections IM in 150 healthy subjects. Each study's vaccine dose level will be evaluated with and without adjuvant.

Interim Results

The Lancet reported interim results for this clinical trial.

The SCB-2019 vaccine, comprising S-Trimer protein formulated with either AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses against SARS-CoV-2, with high viral neutralizing activity. Both adjuvanted vaccine formulations were well tolerated and are suitable for further clinical development.